MYCOPHENOLATE MOFETIL TEVA 250 mg, hard capsule 100 capsules
Active ingredients: Mycophenolate mofetil
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule100 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MYCOPHENOLATE MOFETIL TEVA 250 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC PVDC aluminium de 100 gélule(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Mar 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63352659CIP73850041CIP133400938500417Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MYCOPHÉNOLATE MOFÉTILgélule | 250 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.